MCID: ACT105
MIFTS: 58

Acute Mountain Sickness

Categories: Blood diseases, Rare diseases

Aliases & Classifications for Acute Mountain Sickness

MalaCards integrated aliases for Acute Mountain Sickness:

Name: Acute Mountain Sickness 54 74
High Altitude Pulmonary Edema 54 60 17 74
Altitude Sickness 54 17 74
High Altitude Cerebral Edema 54 74
Mountain Sickness 54 74
Altitude Anoxia 54

Characteristics:

Orphanet epidemiological data:

60
high altitude pulmonary edema
Prevalence: 1-9/1000000 (Europe);

Classifications:



External Ids:

ICD10 via Orphanet 35 J81
UMLS via Orphanet 75 C0340100
Orphanet 60 ORPHA330012

Summaries for Acute Mountain Sickness

MalaCards based summary : Acute Mountain Sickness, also known as high altitude pulmonary edema, is related to chronic mountain sickness and hypoxia, and has symptoms including dyspnea, apnea and cheyne-stokes respiration. An important gene associated with Acute Mountain Sickness is ACE (Angiotensin I Converting Enzyme), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and Pathways in cancer. The drugs Acetazolamide and Ibuprofen have been mentioned in the context of this disorder. Affiliated tissues include lung, endothelial and heart, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 77 Altitude sickness, the mildest form being acute mountain sickness (AMS), is the negative health effect... more...

Related Diseases for Acute Mountain Sickness

Diseases in the Acute Mountain Sickness family:

Chronic Mountain Sickness

Diseases related to Acute Mountain Sickness via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)
# Related Disease Score Top Affiliating Genes
1 chronic mountain sickness 32.4 EDN1 NOS3 VEGFA
2 hypoxia 30.6 EGLN1 HIF1A HIF1AN VEGFA VHL
3 pulmonary edema 30.5 ACE EDN1 NOS3 PIK3C2A
4 pulmonary hypertension 30.0 ACE EDN1 HIF1A NOS3
5 polycythemia 29.8 EGLN1 HIF1A VHL
6 diabetes mellitus 29.4 ACE AGTR1 EDN1 NOS3 PIK3C2A VEGFA
7 heart disease 29.0 ACE AGTR1 EDN1 HSPA1A NOS3 PIK3C2A
8 myocardial infarction 28.5 ACE ADRB2 AGTR1 EDN1 HIF1A MB
9 pulmonary edema of mountaineers 11.4
10 unilateral absence of a pulmonary artery 11.3
11 headache 10.5
12 patent foramen ovale 10.4
13 hemifacial spasm 10.4 NOS3 VEGFA
14 intravascular papillary endothelial hyperplasia 10.4 HIF1A VEGFA
15 patellar tendinitis 10.4 NOS3 VEGFA
16 peripheral artery disease 10.4 ACE NOS3 VEGFA
17 large cell carcinoma with rhabdoid phenotype 10.3 ENO2 VEGFA
18 renal artery disease 10.3 ACE AGTR1 NOS3
19 hypertensive nephropathy 10.3 ACE AGTR1 VEGFA
20 ischemic heart disease 10.3 ACE AGTR1 NOS3
21 acute anterolateral myocardial infarction 10.3 ACE PIK3C2A
22 diastolic heart failure 10.3 ACE AGTR1 NOS3
23 mitral valve disease 10.3 ACE AGTR1 NOS3
24 sexual disorder 10.3 ACE EDN1 NOS3
25 hepatopulmonary syndrome 10.2 EDN1 NOS3 VEGFA
26 virus associated hemophagocytic syndrome 10.2 MB PIK3C2A
27 pulmonary embolism 10.2
28 intermediate coronary syndrome 10.2 ACE MB PIK3C2A
29 orbital cancer 10.2 ENO2 MB
30 pseudohyperkalemia, familial, 2, due to red cell leak 10.2 ACE MB PIK3C2A
31 anxiety 10.2
32 interstitial myocarditis 10.2 MB PIK3C2A
33 malignant triton tumor 10.2 MB S100B
34 renal hypertension 10.2 ACE AGTR1 EDN1
35 pericardial effusion 10.2 HIF1A PIK3C2A VEGFA
36 oligohydramnios 10.1 ACE AGTR1 EDN1
37 autosomal dominant polycystic kidney disease 10.1 ACE EDN1 NOS3 VEGFA
38 down syndrome 10.1
39 angiokeratoma circumscriptum 10.1 FLT1 VEGFA
40 intracranial cysts 10.1 ENO2 S100B
41 vascular disease 10.1 ACE EDN1 NOS3 VEGFA
42 coronary artery vasospasm 10.1 EDN1 NOS3 PIK3C2A
43 intracranial hypertension 10.1
44 cytokine deficiency 10.1
45 bednar tumor 10.1 ENO2 S100B
46 retinal vascular disease 10.1 ACE FLT1 VEGFA
47 renovascular hypertension 10.1 ACE AGTR1 EDN1 NOS3
48 ischemic optic neuropathy 10.1 ACE AGTR1 EDN1 NOS3
49 nonarteritic anterior ischemic optic neuropathy 10.1 ACE AGTR1 EDN1 NOS3
50 urinary system disease 10.1 ACE AGTR1 EDN1 VEGFA

Graphical network of the top 20 diseases related to Acute Mountain Sickness:



Diseases related to Acute Mountain Sickness

Symptoms & Phenotypes for Acute Mountain Sickness

UMLS symptoms related to Acute Mountain Sickness:


dyspnea, apnea, cheyne-stokes respiration, coughing, hoarseness

MGI Mouse Phenotypes related to Acute Mountain Sickness:

47 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.39 ACE ADRB2 AGTR1 BDKRB2 EDN1 EGLN1
2 homeostasis/metabolism MP:0005376 10.36 ACE ADRB2 AGTR1 BDKRB2 CCK EDN1
3 cellular MP:0005384 10.35 ADRB2 BDKRB2 EGLN1 ENO2 FLT1 HIF1A
4 growth/size/body region MP:0005378 10.34 ACE ADRB2 AGTR1 EDN1 EGLN1 ENO2
5 behavior/neurological MP:0005386 10.3 ACE ADRB2 AGTR1 BDKRB2 ENO2 FLT1
6 hematopoietic system MP:0005397 10.26 ACE ADRB2 AGTR1 BDKRB2 EGLN1 FLT1
7 immune system MP:0005387 10.17 ACE ADRB2 AGTR1 BDKRB2 EGLN1 FLT1
8 endocrine/exocrine gland MP:0005379 10.16 ACE ADRB2 BDKRB2 CCK EDN1 HIF1A
9 mortality/aging MP:0010768 10.15 ACE AGTR1 BDKRB2 EDN1 EGLN1 FLT1
10 embryo MP:0005380 10.13 EDN1 EGLN1 FLT1 HIF1A MB PIK3C2A
11 adipose tissue MP:0005375 10.11 ACE ADRB2 AGTR1 BDKRB2 HIF1AN NOS3
12 muscle MP:0005369 10.02 ADRB2 EDN1 EGLN1 FLT1 HIF1A HIF1AN
13 nervous system MP:0003631 9.96 ADRB2 AGTR1 CCK EDN1 EGLN1 ENO2
14 liver/biliary system MP:0005370 9.95 ACE EGLN1 HIF1A HIF1AN NOS3 VEGFA
15 normal MP:0002873 9.81 BDKRB2 EDN1 FLT1 HIF1A HIF1AN NOS3
16 renal/urinary system MP:0005367 9.7 ACE AGTR1 BDKRB2 CCK EDN1 EGLN1
17 respiratory system MP:0005388 9.17 EGLN1 ENO2 HIF1A HIF1AN MB NOS3

Drugs & Therapeutics for Acute Mountain Sickness

Drugs for Acute Mountain Sickness (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 138)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetazolamide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 59-66-5 1986
2
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15687-27-1 3672
3
Acetaminophen Approved Phase 4 103-90-2 1983
4
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 1177-87-3
5
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 1,Phase 2 50-02-2 5743
6
Sodium Citrate Approved, Investigational Phase 4 68-04-2
7
Riociguat Approved Phase 4 625115-55-1
8
Methazolamide Approved Phase 4,Phase 1,Phase 2 554-57-4 4100
9
Nifedipine Approved Phase 4 21829-25-4 4485
10
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
11
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
12
Acetylcysteine Approved, Investigational Phase 4,Phase 1,Phase 2 616-91-1 12035
13
Metformin Approved Phase 4 657-24-9 14219 4091
14
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
15
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
16
Quercetin Experimental, Investigational Phase 4 117-39-5 5280343
17 Carbonic Anhydrase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
18 Natriuretic Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
19 diuretics Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
20 Anticonvulsants Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
21 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
29 Antiemetics Phase 4,Phase 1,Phase 2,Not Applicable
30 Gastrointestinal Agents Phase 4,Phase 1,Phase 2,Not Applicable
31 Epoetin alfa Phase 4 113427-24-0
32 Hematinics Phase 4,Not Applicable
33 Antipyretics Phase 4
34 HIV Protease Inhibitors Phase 4,Phase 1,Phase 2
35 Hormones Phase 4,Phase 3,Phase 1,Phase 2
36
protease inhibitors Phase 4,Phase 1,Phase 2
37 BB 1101 Phase 4,Phase 1,Phase 2
38 Antineoplastic Agents, Hormonal Phase 4,Phase 1,Phase 2
39 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
40 glucocorticoids Phase 4,Phase 3,Phase 1,Phase 2
41 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
42 Chelating Agents Phase 4
43 Sildenafil Citrate Phase 4 171599-83-0
44 Vasodilator Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
45 Citrate Phase 4
46 Anticoagulants Phase 4
47 Phosphodiesterase 5 Inhibitors Phase 4,Phase 1,Phase 2,Not Applicable
48 Calcium, Dietary Phase 4
49 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
50 Performance-Enhancing Substances Phase 4

Interventional clinical trials:

(show top 50) (show all 117)
# Name Status NCT ID Phase Drugs
1 Erythropoietin in the Prevention of Acute Mountain Sickness Completed NCT01665781 Phase 4 Erythropoietin
2 A Trial of Acetazolamide Versus Placebo in Preventing Mountain Sickness During Rapid Ascent Completed NCT01418157 Phase 4 Acetazolamide;Placebo
3 Ibuprofen vs Acetaminophen for AMS Prevention Completed NCT02244437 Phase 4 Ibuprofen;Acetaminophen
4 Altitude Related Illness In Patients With Respiratory Disease Completed NCT02450968 Phase 4 Dexamethasone;Placebo
5 Acetazolamide for the Prevention of High Altitude Illness: a Comparison of Dosing Completed NCT01993667 Phase 4 Low Dose Acetazolamide;Normal Dose Acetazolamide
6 Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness Completed NCT00627965 Phase 4 Sildenafil citrate;Placebo
7 Efficacy Study of Riociguat and Its Effects on Exercise Performance and Pulmonary Artery Pressure at High Altitude Completed NCT02024386 Phase 4 Riociguat
8 AZ, MZ, and the Pulmonary System Response to Hypoxia Completed NCT02760121 Phase 4 Acetazolamide;Methazolamide;Placebo
9 Treatment of High Altitude Polycythemia by Acetazolamide Completed NCT00424970 Phase 4 acetazolamide
10 Treatment of Patients With the Obstructive Sleep Apnea Syndrome at Altitude Completed NCT00714740 Phase 4 acetazolamide
11 Continuous Positive Airway Pressure and Acetazolamide to Treat Sleep Apnea Syndrome Patients at Altitude Completed NCT00928655 Phase 4 acetazolamide;placebo
12 HIGH Altitude CArdiovascular REsearch in the ANDES Completed NCT01830530 Phase 4 Telmisartan;Nifedipine;placebo
13 Effect Of Acetazolamide On Altitude Related Illness In Patients With Respiratory Disease Completed NCT03156231 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
14 Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years Recruiting NCT03561675 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
15 Effect of Acetazolamide on Postural Control in Patients With Respiratory Disease at Altitude Recruiting NCT03177811 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
16 Effect of Acetazolamide on Postural Control in Lowlanders Older Than 40 Years at Altitude Recruiting NCT03536429 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
17 Effect of Acetazolamide on Right Heart Function at Rest in Lowlanders Older Than 40 Years at Altitude. Recruiting NCT03540914 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
18 Effect of Acetazolamide on Lung Water Content by Ultrasound in Lowlanders Older Than 40 Years at Altitude Recruiting NCT03539367 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
19 Effect of Acetazolamide on Right Heart Function During Exercise in Lowlanders Older Than 40 Years at Altitude Recruiting NCT03537924 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
20 Effect of Acetazolamide on Visuo-motor Learning in Lowlanders Older Than 40 Years at Altitude Recruiting NCT03536520 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
21 Effect of Acetazolamide on Maximal Exercise Performance in Lowlanders Older Than 40 Years at Altitude Recruiting NCT03536455 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
22 Effect of Acetazolamide on Sleep Disordered Breathing in Lowlanders Older Than 40 Years at Altitude Recruiting NCT03536507 Phase 4 ACETAZOLAMIDE oral capsule;Placebo oral capsule
23 Three New Ideas to Protect Special Forces From the Stress of High Altitude Active, not recruiting NCT02463357 Phase 4 Nifedipine extended release;Methazolamide;Metformin;Placebo;Nitrite
24 Effect of Acetazolamide on Subclinical High-Altitude Pulmonary Edema Detected by Lung Ultrasonography Terminated NCT03490916 Phase 4 Acetazolamide;Placebo
25 Induced Changes in Ventilatory Responsiveness and Altitude Exposure Terminated NCT01241513 Phase 4 NAC;Placebo
26 Altitude Sickness Prevention and Efficacy of Comparative Treatments Completed NCT02604173 Phase 3 Budesonide;Acetazolamide;Placebo
27 Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness Completed NCT00664001 Phase 3
28 Drug Combination on Exercise Performance at High Altitude Completed NCT01902758 Phase 2, Phase 3 ambrisentan and theophylline;placebo
29 Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS) Completed NCT01171794 Phase 3 Ibuprofen;Placebo
30 Inhaled Budesonide for Altitude Illness Prevention Withdrawn NCT02941510 Phase 3 Budesonide
31 NSAID RCT for Prevention of Altitude Sickness Unknown status NCT01606527 Phase 2 Ibuprofen 600mg orally three times daily
32 Evaluation of the Prevention and Treatment Effects of Chinese Medicine on High Altitude Illness Unknown status NCT01682551 Phase 2 Chinese Medicine;Acetalozamide
33 Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness Completed NCT03270787 Phase 1, Phase 2 Placebo;Compound danshen dripping pills
34 Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness Completed NCT01536288 Phase 2 Rhodiola crenulata;placebo
35 Prevention of High Altitude Pulmonary Edema Completed NCT00274430 Phase 1, Phase 2 dexamethasone 8 mg bid;tadalafil 10mg bid
36 Study of Cobalt's Role in Excessive Erythrocytosis Among High Altitude Dwellers in Cerro de Pasco, Peru Completed NCT01187108 Phase 1, Phase 2 N-acetylcysteine;Acetazolamide;Placebo pills
37 Rapid Acclimatization to Hypoxia at Altitude Completed NCT01702025 Phase 1, Phase 2 Placebo;Aminophylline;Methazolamide;Aminophylline+Methazolamide
38 Evaluation of the Attenuation by Aes-103 of Hypoxia Mediated Decrements in Endurance Exercise Performance Completed NCT01871142 Phase 1, Phase 2 Placebo;Aes-103;Aes-103
39 T89 in Prevention and Treatment of Acute Mountain Sickness (AMS) During Rapid Ascent Recruiting NCT03621410 Phase 2 T89 225 mg group;Placebo;T89 300 mg group
40 Safety and Efficacy of T89 in Prevention and Treatment of Adults With Acute Mountain Sickness (AMS) Recruiting NCT03552263 Phase 2 T89 capsule;Placebo capsule
41 Effects of Non-steroidal Anti-inflammatory Drugs (NSAIDS) on Acclimatization to High Altitude Unknown status NCT02233582 Phase 1 Ibuprofen
42 Altitude Sickness Prevention With Ibuprofen Relative to Acetazolamide and Treatment Efficacy Completed NCT03154645 Phase 1 Ibuprofen;Acetazolamide
43 Inhaled Budesonide and Acute Mountain Sickness Completed NCT02811016 Phase 1 Budesonide 200;Budesonide 800;Placebo
44 Sickness Evaluation at Altitude With Acetazolamide at Relative Dosages Completed NCT03424226 Phase 1 Acetazolamide
45 A Study to Test the Safety of Combined Dosing With Aminophylline and Ambrisentan in Exercising Healthy Human Volunteers at Simulated High Altitude Completed NCT01794078 Phase 1 Aminophylline 400 mg;Ambrisentan 5 mg
46 Safety Evaluation of Aminophylline and Methazolamide Completed NCT01587027 Phase 1 Aminophylline;Methazolamide;Aminophylline and Methazolamide
47 Effects of Bosentan (Tracleer) in the Course of Pulmonary Artery Hypertension Induced by Hypoxia Completed NCT00260819 Phase 1 Bosentan;Bosentam TRACLEER
48 Hypoxia Impairs Endothelial Function in HAPEs Completed NCT00176007 Phase 1
49 A Clinical Trial of the Clinical Effects of Hyperbaric Oxygen Therapy in Thai Autistic Children Completed NCT00670891 Phase 1
50 The Safety Evaluation of Drug Combinations Against High Altitude Pulmonary Hypertension Completed NCT01566565 Phase 1 Theophylline and Bambuterol

Search NIH Clinical Center for Acute Mountain Sickness

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Acute Mountain Sickness

Anatomical Context for Acute Mountain Sickness

MalaCards organs/tissues related to Acute Mountain Sickness:

42
Lung, Endothelial, Heart, Testes, Brain, Skeletal Muscle, Pituitary

Publications for Acute Mountain Sickness

Articles related to Acute Mountain Sickness:

(show top 50) (show all 959)
# Title Authors Year
1
The Effect of an Expiratory Resistance Mask with Dead Space on Sleep, Acute Mountain Sickness, Cognition, and Ventilatory Acclimatization in Normobaric Hypoxia. ( 30720346 )
2019
2
The usefulness of prophylactic use of acetazolamide in subjects with acute mountain sickness. ( 30839503 )
2019
3
Physiological Responses in Humans Acutely Exposed to High Altitude (3480 m): Minute Ventilation and Oxygenation Are Predictive for the Development of Acute Mountain Sickness. ( 30896981 )
2019
4
Delayed-Onset High Altitude Pulmonary Edema: A Case Report. ( 30642713 )
2019
5
Association between the IL1R2 rs2072472 polymorphism and high-altitude pulmonary edema risk. ( 30672138 )
2019
6
Successful Summit of Two 8000 m Peaks After Recent High Altitude Pulmonary Edema. ( 30852106 )
2019
7
Elevated Vasodilatory Cyclases and Shorter Telomere Length Contribute to High-Altitude Pulmonary Edema. ( 29443612 )
2018
8
Diagnosing Acute Mountain Sickness-Reply. ( 29634826 )
2018
9
Electronic Nose Technology Fails to Sniff Out Acute Mountain Sickness. ( 29641295 )
2018
10
Increased Cytokines at High Altitude: Lack of Effect of Ibuprofen on Acute Mountain Sickness, Physiological Variables, or Cytokine Levels. ( 29924642 )
2018
11
Impact of Sleeping Altitude on Symptoms of Acute Mountain Sickness on Mt. Fuji. ( 29741971 )
2018
12
Optic nerve oedema at high altitude occurs independent of acute mountain sickness. ( 29973364 )
2018
13
The 2018 Lake Louise Acute Mountain Sickness Score. ( 29583031 )
2018
14
Diagnosing Acute Mountain Sickness. ( 29634823 )
2018
15
Sequencing the exons of human glucocorticoid receptor (NR3C1) gene in Han Chinese with high-altitude pulmonary edema. ( 29587872 )
2018
16
Plasma proteomic study of acute mountain sickness susceptible and resistant individuals. ( 29352170 )
2018
17
Efficacy of Dexamethasone in Preventing Acute Mountain Sickness in COPD Patients: Randomized Trial. ( 29909285 )
2018
18
Exploration of Acute Phase Proteins and Inflammatory Cytokines in Early Stage Diagnosis of Acute Mountain Sickness. ( 29608374 )
2018
19
The relationship between anxiety and acute mountain sickness. ( 29927953 )
2018
20
Single Question Is Useful for Identifying Acute Mountain Sickness in Travelers at High Altitude. ( 29763259 )
2018
21
Pharmacological interventions for preventing acute mountain sickness: a network meta-analysis and trial sequential analysis of randomized clinical trials. ( 29166795 )
2018
22
Association between acute mountain sickness (AMS) and age: a meta-analysis. ( 29747689 )
2018
23
HMOX1 Promoter Microsatellite Polymorphism and High Altitude Pulmonary Edema in Han Chinese Men. ( 29398188 )
2018
24
Transcriptomic profiling reveals gene expression kinetics in patients with hypoxia and high altitude pulmonary edema. ( 29366758 )
2018
25
Response to: Comment on "Soluble Urokinase-Type Plasminogen Activator Receptor Plasma Concentration May Predict Susceptibility to High Altitude Pulmonary Edema". ( 29853793 )
2018
26
Understanding molecular mechanisms of Rhodiola rosea for the treatment of acute mountain sickness through computational approaches (a STROBE-compliant article). ( 30278484 )
2018
27
Advances in the available non-biological pharmacotherapy prevention and treatment of acute mountain sickness and high altitude cerebral and pulmonary oedema. ( 30307756 )
2018
28
Occurrence of Acute Mountain Sickness in Nonclimbing Tourists at Mount Mitchell, North Carolina (2037 m). ( 30376383 )
2018
29
Changes of hemodynamic and cerebral oxygenation after exercise in normobaric and hypobaric hypoxia: associations with acute mountain sickness. ( 30479778 )
2018
30
Acute Mountain Sickness is Reduced Following 2 Days of Staging During Subsequent Ascent to 4300 m. ( 30517038 )
2018
31
Acute mountain sickness (AMS) in a Nepali pilgrim after rapid ascent to a sacred lake (4380 m) in the Himalayas. ( 30567154 )
2018
32
Acute Mountain Sickness Is Associated With a High Ratio of Endogenous Testosterone to Estradiol After High-Altitude Exposure at 3,700 m in Young Chinese Men. ( 30740062 )
2018
33
Characteristics of Headache and Relationship to Acute Mountain Sickness at 4559 Meters. ( 30067102 )
2018
34
The effects of respiratory inhaled drugs on the prevention of acute mountain sickness. ( 30095637 )
2018
35
Ginkgo biloba extract for prevention of acute mountain sickness: a systematic review and meta-analysis of randomised controlled trials. ( 30121603 )
2018
36
Re: "Increased Cytokines at High Altitude: Lack of Effect of Ibuprofen on Acute Mountain Sickness, Physiological Variables, or Cytokine Levels" by Lundeberg, et al. (High Alt Med Biol 2018 19:249-258). ( 30153038 )
2018
37
Association between decreased osteopontin and acute mountain sickness upon rapid ascent to 3500 m among young Chinese men. ( 30165389 )
2018
38
The Smell of Hypoxia: using an electronic nose at altitude and proof of concept of its role in the prediction and diagnosis of acute mountain sickness. ( 30187693 )
2018
39
Response to Burtscher re: "Increased Cytokines at High Altitude: Lack of Effect of Ibuprofen on Acute Mountain Sickness, Physiological Variables, or Cytokine Levels". ( 30239230 )
2018
40
The plasma level changes of VEGF and soluble VEGF receptor-1 are associated with high-altitude pulmonary edema. ( 29593196 )
2018
41
From Ocean Deep to Mountain High: Similar Computed Tomography Findings in Immersion and High-Altitude Pulmonary Edema. ( 30044644 )
2018
42
Higher ascent, trouble breathing: High altitude pulmonary edema (HAPE). ( 30167070 )
2018
43
Clinical, Laboratory and Imaging Features of High Altitude Pulmonary Edema in Tibetan Plateau. ( 30266106 )
2018
44
NR3C2 Gene is Associated with Susceptibility to High-Altitude Pulmonary Edema in Han Chinese. ( 30292562 )
2018
45
Changes in corneal thickness in patients with high-altitude pulmonary edema after systemic oxygen therapy. ( 30355859 )
2018
46
Lung Ultrasound Is Accurate for the Diagnosis of High-Altitude Pulmonary Edema: A Prospective Study. ( 30364105 )
2018
47
Relationship between Smoking and Acute Mountain Sickness: A Meta-Analysis of Observational Studies. ( 29259975 )
2017
48
Unilateral High-Altitude Pulmonary Edema. ( 28837778 )
2017
49
Remote ischemic preconditioning does not prevent acute mountain sickness after rapid ascent to 3450 m. ( 28798201 )
2017
50
Acute mountain sickness amongst tourists to Lhasa. ( 28149514 )
2017

Variations for Acute Mountain Sickness

Expression for Acute Mountain Sickness

Search GEO for disease gene expression data for Acute Mountain Sickness.

Pathways for Acute Mountain Sickness

Pathways related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.04 EGLN1 HIF1A HIF1AN HSPA1A HSPA1B VEGFA
2 12.74 AGTR1 BDKRB2 EGLN1 HIF1A VEGFA VHL
3
Show member pathways
12.46 EGLN1 HIF1A VEGFA VHL
4 12.14 ADRB2 AGTR1 BDKRB2 NOS3
5
Show member pathways
12.11 FLT1 NOS3 PIK3C2A VEGFA
6 11.81 AGTR1 EDN1 NOS3 VEGFA
7
Show member pathways
11.77 FLT1 HIF1A NOS3 VEGFA VHL
8 11.72 EGLN1 FLT1 HIF1A HIF1AN NOS3
9
Show member pathways
11.7 ACE AGTR1 BDKRB2 NOS3
10
Show member pathways
11.69 FLT1 NOS3 PIK3C2A
11 11.6 ACE ADRB2 AGTR1
12 11.57 EDN1 EGLN1 HIF1A VEGFA
13 11.56 EDN1 EGLN1 ENO2 FLT1 HIF1A NOS3
14
Show member pathways
11.52 HSPA1A HSPA1B NOS3
15 11.22 EDN1 EGLN1 HIF1A HIF1AN VEGFA
16
Show member pathways
11.18 EDN1 HIF1A VEGFA
17 11.09 EGLN1 FLT1 HIF1AN VEGFA VHL
18 11.01 EDN1 EGLN1 HIF1A HIF1AN HSPA1A HSPA1B
19 11 FLT1 HIF1A NOS3 VEGFA
20 10.83 HIF1A HIF1AN VHL
21 10.56 HIF1A HIF1AN VEGFA
22 10.49 MB NOS3

GO Terms for Acute Mountain Sickness

Cellular components related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.47 ACE EDN1 EGLN1 ENO2 FLT1 HIF1A

Biological processes related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.95 FLT1 HIF1A NOS3 VEGFA
2 negative regulation of apoptotic process GO:0043066 9.91 HIF1A HSPA1A HSPA1B VEGFA VHL
3 positive regulation of angiogenesis GO:0045766 9.86 FLT1 HIF1A NOS3 VEGFA
4 regulation of blood pressure GO:0008217 9.8 ACE EDN1 NOS3
5 negative regulation of gene expression GO:0010629 9.8 ACE EDN1 HIF1A VEGFA VHL
6 positive regulation of MAP kinase activity GO:0043406 9.79 EDN1 FLT1 VEGFA
7 cellular response to hypoxia GO:0071456 9.78 EDN1 HIF1A S100B VEGFA
8 positive regulation of blood vessel endothelial cell migration GO:0043536 9.75 HIF1A NOS3 VEGFA
9 vascular endothelial growth factor signaling pathway GO:0038084 9.65 FLT1 VEGFA
10 response to hypoxia GO:0001666 9.65 EDN1 EGLN1 HIF1A MB VEGFA
11 negative regulation of inclusion body assembly GO:0090084 9.64 HSPA1A HSPA1B
12 positive regulation of tumor necrosis factor-mediated signaling pathway GO:1903265 9.64 HSPA1A HSPA1B
13 regulation of cell death GO:0010941 9.63 HSPA1A HSPA1B
14 positive regulation of erythrocyte differentiation GO:0045648 9.63 HIF1A HSPA1A HSPA1B
15 oxygen homeostasis GO:0032364 9.61 EGLN1 HIF1A
16 positive regulation of receptor biosynthetic process GO:0010870 9.61 EDN1 HIF1A
17 blood vessel morphogenesis GO:0048514 9.61 EDN1 FLT1 HIF1A
18 cellular heat acclimation GO:0070370 9.6 HSPA1A HSPA1B
19 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.59 EDN1 NOS3
20 regulation of systemic arterial blood pressure by renin-angiotensin GO:0003081 9.58 ACE AGTR1
21 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.57 HIF1A VEGFA
22 negative regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061428 9.55 HIF1AN VHL
23 positive regulation of microtubule nucleation GO:0090063 9.54 HSPA1A HSPA1B
24 positive regulation of peptidyl-tyrosine autophosphorylation GO:1900086 9.52 ACE VEGFA
25 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.5 FLT1 HIF1A VEGFA
26 positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway GO:0070434 9.49 HSPA1A HSPA1B
27 positive regulation of chemokine-mediated signaling pathway GO:0070101 9.37 EDN1 HIF1A
28 regulation of blood vessel diameter GO:0097746 9.33 ACE ADRB2 AGTR1
29 regulation of vasoconstriction GO:0019229 9.26 ACE AGTR1 BDKRB2 EDN1
30 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.02 EGLN1 HIF1A HIF1AN VEGFA VHL
31 positive regulation of cell proliferation GO:0008284 10.05 CCK EDN1 FLT1 S100B VEGFA
32 positive regulation of gene expression GO:0010628 10.02 HIF1A HSPA1A HSPA1B NOS3 VEGFA

Molecular functions related to Acute Mountain Sickness according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 C3HC4-type RING finger domain binding GO:0055131 9.16 HSPA1A HSPA1B
2 enzyme binding GO:0019899 9.1 ADRB2 EGLN1 HIF1A HSPA1A HSPA1B VHL
3 bradykinin receptor binding GO:0031711 8.96 ACE AGTR1

Sources for Acute Mountain Sickness

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....